Human Cytomegalovirus Envelope Glycoprotein B - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509249030

Publication Date:

September 11, 2024

Pages:

101

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Human Cytomegalovirus Envelope Glycoprotein B was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Human Cytomegalovirus Envelope Glycoprotein B was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Human Cytomegalovirus Envelope Glycoprotein B was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Human Cytomegalovirus Envelope Glycoprotein B include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Cytomegalovirus Envelope Glycoprotein B by region & country, by Type, and by Application.
The Human Cytomegalovirus Envelope Glycoprotein B market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Cytomegalovirus Envelope Glycoprotein B.
麻豆原创 Segmentation
By Company
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type:
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segment by Application
Infectious Disease
Oncology
Women's Health
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Human Cytomegalovirus Envelope Glycoprotein B Product Introduction
1.2 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size Forecast
1.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2019-2030)
1.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume (2019-2030)
1.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Price (2019-2030)
1.3 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Trends & Drivers
1.3.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
1.3.2 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Drivers & Opportunity
1.3.3 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Challenges
1.3.4 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Players Revenue Ranking (2023)
2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Company (2019-2024)
2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Players Sales Volume Ranking (2023)
2.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Company Players (2019-2024)
2.5 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Company (2019-2024)
2.6 Key Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Cytomegalovirus Envelope Glycoprotein B
2.9 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Competitive Analysis
2.9.1 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Cytomegalovirus Envelope Glycoprotein B Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Cytomegalovirus Envelope Glycoprotein B as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CSJ-148
3.1.2 CyMVectin
3.1.3 TRL-345
3.1.4 PPCM
3.1.5 Cytomegalovirus Vaccine
3.1.6 Others
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type
3.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value, by Type (2019-2030)
3.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value, by Type (%) (2019-2030)
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type
3.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume, by Type (2019-2030)
3.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume, by Type (%) (2019-2030)
3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Infectious Disease
4.1.2 Oncology
4.1.3 Women's Health
4.1.4 Others
4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value, by Application (2019-2030)
4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value, by Application (%) (2019-2030)
4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application
4.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume, by Application (2019-2030)
4.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume, by Application (%) (2019-2030)
4.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region
5.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2019-2024)
5.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2025-2030)
5.1.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (%), (2019-2030)
5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Region
5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Region (2019-2024)
5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Region (2025-2030)
5.2.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Region (%), (2019-2030)
5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
5.4.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
5.5.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
5.6.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
5.7.2 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
5.8.2 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Human Cytomegalovirus Envelope Glycoprotein B Sales Value
6.2.1 Key Countries/Regions Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.2.2 Key Countries/Regions Human Cytomegalovirus Envelope Glycoprotein B Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.3.2 United States Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.4.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.5.2 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.5.3 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.6.2 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.7.2 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.8.2 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value, 2019-2030
6.9.2 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (%), 2023 VS 2030
6.9.3 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Astellas Pharma Inc.
7.1.1 Astellas Pharma Inc. Company Information
7.1.2 Astellas Pharma Inc. Introduction and Business Overview
7.1.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Offerings
7.1.5 Astellas Pharma Inc. Recent Development
7.2 Trellis Bioscience, Inc.
7.2.1 Trellis Bioscience, Inc. Company Information
7.2.2 Trellis Bioscience, Inc. Introduction and Business Overview
7.2.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Offerings
7.2.5 Trellis Bioscience, Inc. Recent Development
7.3 Vakzine Projekt Management GmbH
7.3.1 Vakzine Projekt Management GmbH Company Information
7.3.2 Vakzine Projekt Management GmbH Introduction and Business Overview
7.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Offerings
7.3.5 Vakzine Projekt Management GmbH Recent Development
7.4 VBI Vaccine Inc
7.4.1 VBI Vaccine Inc Company Information
7.4.2 VBI Vaccine Inc Introduction and Business Overview
7.4.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
7.4.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Offerings
7.4.5 VBI Vaccine Inc Recent Development
7.5 Vical Incorporated
7.5.1 Vical Incorporated Company Information
7.5.2 Vical Incorporated Introduction and Business Overview
7.5.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Offerings
7.5.5 Vical Incorporated Recent Development
8 Industry Chain Analysis
8.1 Human Cytomegalovirus Envelope Glycoprotein B Industrial Chain
8.2 Human Cytomegalovirus Envelope Glycoprotein B Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Cytomegalovirus Envelope Glycoprotein B Sales Model
8.5.2 Sales Channel
8.5.3 Human Cytomegalovirus Envelope Glycoprotein B Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.